GLENMARKGlenmark Pharmaceuticals Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)
₹2,239.50
▲ 0.18%Decent
Price & Volume
Loading chart…
Key Ratios
Market Cap (₹ cr)63,086.00
P/E46.33
P/B6.00
PEG0.01
ROE %14.07
ROCE %36.00
Debt / Equity0.06
EPS48.25
Revenue Growth %14.30
Profit Growth %6,575.00
Dividend Yield %0.22
Promoter Holding %48.97
FII Holding %27.25
DII Holding %—
Beta0.26
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
| Double Bottom | LONG | 70% | ₹2,239.50 | ₹2,101.00 | ₹2,368.80 | 0.93 |
HOLDConviction 71%
The picture
- • Profit growth: 6575.0% YoY
- • ROCE: 36.0%
- • Debt/Equity: 0.06
- • MACD: bullish
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • Double Bottom signal (setup quality 70%)
Bull case
- • Profit growth: 6575.0% YoY
- • ROCE: 36.0%
- • Debt/Equity: 0.06
- • MACD: bullish
Bear case
- • Dividend yield: 0.22%
- • Price vs EMA21: below
- • Price vs SMA50: below
- • 3-month return: -0.0%
Key risks
- • Dividend yield: 0.22%
- • Price vs EMA21: below
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Entry (CMP)
₹2,239.50
Stop Loss
₹2,121.37
risk 5.3%
Target 1 (1.5R)
₹2,416.69
+7.9%
Target 2 (3R)
₹2,593.88
+15.8%
Support (20d)
₹2,142.80
Resistance (52w)
₹2,474.00
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹118.13/share
ATR (volatility)
₹53.97
avg daily range
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹53.97). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.
Score Breakdown
Fundamental
76
Technical
53
Momentum
58
Risk (safety)
77